KAPOSI'S sarcoma is rare in childhood. In a review of 1256 cases by Dutz and Stout (1960) , only 40 (3-2%) were under 6 years. Eighteen of the 40 cases (450o) were from the African continent alone. The first acceptable case of Kaposi's sarcoma in a child was described in a monograph by de Amics in 1882, and cited in a more recent paper by Ronchese (1958) .
Features which differentiate childhood disease from the adult form include the clinical presentation with lymphadenopathy, the sparsely and anomalously distributed cutaneous nodules, the high proportion of females and a fulminatingl course if untreated. In a previous report from this Institute, the varied clinical and pathological features of Kaposi's sarcoma were classified (Taylor et al., 1971a) . The lymphadenopathic form was associated with the childhood cases, but this group constituted a very small proportion of the series. In this paper we report in detail 12 cases of Kaposi's sarcoma in children under 15 years of age seen at the Uganda Cancer Institute (UCI) over the last 7 years.
PATIENTS AND METHODS
Details of presentation, clinical course, response to treatment and other associated features were obtained from the case records. Ten children were referred to the Lymphoma Treatment Centre with a provisional diagnosis of malignant lymphoma and two with a histological diagnosis of Kaposi's sarcoma. The histology sections were reviewed by one of us (R.O.) and classified according to the criteria described previously (Taylor et al., 1971a) .
We define complete remission as disappearance of clinically measurable tumour, partial response as a reduction in tumour volume of at least 5000 and no response as a lesser response, or disease progression.
RESULTS
The clinical details of the 12 patients are given in Table I (Olweny et al., 1974; Vogel et al., 1971) . The primary and subsequent treatments given are detailed in Table I . Six received actinomycin-D alone as their primary treatment regimen, two received a combination of actinomycin-D and vincristine, three received a 3-drug combination consisting of actinomycin-D, vincristine and imidazole carboxamide (DTIC), and one was treated originally with cyclophosphamide. Doses and schedules of chemotherapy are described in detail in previous reports from this centre (Olweny et al., 1974; Vogel et al., 1971 were treated with the actinomycin-D, vincristine and imidazole carboxamide combination all achieved complete tumour regression with remissions lasting 3, 6, and 12 months respectively. The single patient who received cyclophosphamide alone did not respond. Treatment of relapse included: radiotherapy (3); BCNU (2); actinomycin-D and vincristine (3); actinomycin, vincristine and DTIC (4); and DTIC and bleomycin (1). As can be seen in Table  I , the most effective combination in inducing a remission appears to be actinomycin-D, vincristine and DTIC. All 4 patients who later received this combination, having either relapsed or responded incompletely to other forms of treatment, responded with complete tumour regression lasting 6+, 9, 12 and 13 months. In the majority of patients relapse was at the same site as the original tumour suggesting incomplete eradication of tumour. (Dutz and Stout, 1960) . In a more recent report of 51 autopsies in childhood cases from East Africa, 20 had lymph node enlargement, 5 had skin nodules as well as lymph node enlargement, and 2 had lymph node and ocular involvement as the major clinical features of the disease (Slavin et al., 1970) . The skin nodules when present are sparse and distributed over anomalous sites. The eyelids, lacrimal glands, jaw, parotid and salivary glands are areas of predilection and sometimes patients present with Mickulicz syndrome. The reason for propensity to glandular involvement in African children is not clearly understood. Some authors have tended to regard Kaposi's sarcoma as a disease arising in the reticuloendothelial system. This is based on the observation of occasional co-existence of Kaposi's sarcoma and lymphoproliferative disorders such as Hodgkin's disease, lymphosarcoma, mycosis fungoides and leukaemia (Cox and Helwig, 1959; Moertel, 1966) . However, this association is more commonly seen in adult whites than in Africans, while lymph node disease in general is commoner in the Africans than in whites. The presentation with generalized lymphadenopathy may lead to wrong diagnosis. Tuberculosis and/or Hodgkin's disease are the frequent referring diagnoses; both being prevalent in tropical Africa. Ten of the patients reported here were referred with a provisional diagnosis of malignant lymphoma. Kaposi's sarcoma should therefore be included in the differential diagnosis of any child with lymph node enlargement.
A second difference between childhood and adult Kaposi's sarcoma is the greater frequency of females with the disease. Most authors report a male: female ratio of 3: 1 (Dutz and Stout, 1960; Slavin et al., 1970; Templeton, 1972) . This is in marked contrast to the adult series where the ratio is 13: 1 (Olweny et al., 1974) . In the present series the male: female ratio is almost 1 : 1. So far there is no satisfactory explanation for the sex distribution. Sex hormones have been suggested as possibly protecting the post-pubertal females, but treatment with oestrogens has yielded no beneficial results, and some patients have developed the disease while pregnant (Taylor et al., 1971b) . However, review of childhood cases in Uganda prior to 1967 revealed that all 9 recorded cases were males (Davies and Lothe, 1962) .
The histological features observed in this small series also deserve mention. All 12 patients had the mixed cell type histological picture which is consistent with an earlier report where lymphadenopathic disease was also exclusively of mixed cellular type (Taylor et al., 1971b) . This histological appearance occurs overall in some 70% of adult Kaposi sarcoma patients in Uganda (Olweny et al., 1974). 559 It is generally agreed that lymphadenopathic childhood Kaposi's sarcoma is disseminated and aggressively malignant. If not treated, death will almost certainly ensue within one year. The response to treatment has been varied and difficult to assess as no uniform approach has been used. However, two patients treated only with actinomycin-D are alive and apparently disease free at 52 + and 68 + months respectively, so that there is no doubt that chemotherapy alone can be highly effective therapy. The combination of actinomycin-D, vincristine and DTIC may prove to be even more effective since it has induced complete remission in 3 out of 3 patients when used as primary therapy and 4 out of 4 patients with recurrent tumour. In one of these patients this combination was used after a partial response had been induced by radiotherapy, and the latter form of treatinent, although used only for treatment of tumours not responding or responding partially to chemotherapy, has also proved useful in the few patients who received it. In appropriate clinical circumstances radiotherapy may further enhance the efficacy of chemotherapy, and until further data become available, a combination of radiotherapy (where facilities exist) and the three drug combination is probably the treatment of choice.
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